Preferred Label : Degarelix Acetate;
NCIt synonyms : FE200486 Acetate Hydrate; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-
pyridinyl)-D-alanyl-L- seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-
L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-
lysyl-L-prolyl, Acetate, Hydrate;
NCIt definition : The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing
hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors
located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing
secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing
testosterone production by interstitial (Leydig) cells in the testes.;
UNII : I18S89P20R;
InChIKey : QMBXFMRFTMPFEY-XDPVAHNXSA-N;
CAS number : 934246-14-7;
Drug name : Gonax;
Chemical formula : C82H103ClN18O16.C2H4O2.H2O;
Origin ID : C80443;
UMLS CUI : C2718533;
Automatic exact mappings (from CISMeF team)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT
concept_is_in_subset
has_free_acid_or_base_form
has_target
is_component_of_chemotherapy_regimen
is_salt_form_of
https://www.has-sante.fr/jcms/p_3242183/fr/firmagon
2021
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
degarelix
Degarelix Acetate
degarelix
injections, subcutaneous
hormone antagonists
prostatic neoplasms
neoplasms, hormone-dependent
advanced hormone-dependent prostate cancer
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
oligopeptides
---
http://www.has-sante.fr/portail/jcms/c_2017117/fr/firmagon
http://www.has-sante.fr/portail/display.jsp?id=c_866783
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-02/firmagon_ct_6725.pdf
2015
false
France
French
Degarelix Acetate
advanced hormone-dependent prostate cancer
Hormone-dependent prostate cancer
Advanced Malignant Neoplasm
insurance, health, reimbursement
oligopeptides
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
degarelix
gonadotropin-releasing hormone
hormone antagonists
antineoplastic agents
injections, subcutaneous
prostatic neoplasms
neoplasms, hormone-dependent
treatment outcome
degarelix
evaluation of the transparency committee
---